Key result
Recombinant Asporin reduces cardiomyocyte apoptosis and boosts autophagy during ischemia-reperfusion injury.
Why the study?
Myocardial infarction and reperfusion injury drive cardiomyocyte loss and adverse cardiac remodeling, and the protective role of asporin during ischemia-reperfusion stress warranted evaluation.
Recombinant asporin modulates cellular responses to hypoxia and reperfusion in cardiomyocytes, highlighting its potential as a cardioprotective therapy to minimize ischemia-reperfusion injury post-myocardial infarction.
Supports asporin modulation of reperfusion injury; hypothesis-generating in animal models and should not yet change practice.
Background: Myocardial Infarction (MI) remains a leading cause of mortality worldwide, despite advancements in clinical therapies and interventions. MI results from prolonged ischemia, leading to hypoxia-induced damage to cardiac tissue and reperfusion-injury (R/I) that aggravates cardiomyocyte (CM) loss. One key cellular event during this process is accumulation of dysfunctional mitochondria, resulting from environmental hypoxia and subsequent oxidative stress upon reperfusion. Post-MI cardiac-remodeling involves changes in both cellular and extracellular matrix (ECM). Ubiquitin-dependent and independent autophagy are crucial for cardio protection during this phase. The ECM provides structural integrity and functions as a reservoir for signaling molecules. Asporin (ASPN), a small leucine-rich proteoglycan, plays a role in modulating cardiac-remodeling by limiting excessive fibrosis and protecting CMs from cell death. Methods: ischemia-reperfusion (I/R) model simulating MI conditions. Two I/R models were developed using an immortalized human embryonic cardiac cell line to reflect the hypoxia-reperfusion (H/R) phases of MI. In the No-Reoxygenation (No-ReOx) model, cells were subjected to hypoxia for 18 hours, with or without exogenous rASPN. In the Reoxygenation (ReOx) model, cells underwent 18 hours of hypoxia, then 12 hours of reoxygenation (simulating reperfusion), with or without rASPN. Results: Proteomics revealed that ASPN modulates key pathways involved in apoptosis, non-canonical autophagy, and metabolic reprogramming. Additionally, ASPN influenced immune response pathways and significantly affected TGF-β signaling, a central mediator of cardiac fibrosis and remodeling post-MI. These findings indicate that ASPN plays a multifaceted role in regulating cellular responses to hypoxia and R/I. Conclusions: Our H/R model simulates key aspects of MI and R/I. The protective role of ASPN observed in this model suggests it as a promising candidate for developing cardioprotective therapies to minimize R/I and adverse cardiac-remodeling following MI.
No takes yet. Share an insight, caveat, or question.
Rai et al. (2026) studied Myocardial Infarction and Ischemia-Reperfusion Injury. Recombinant Asporin (rASPN) vs. Hypoxia/Ischemia without rASPN was evaluated. Recombinant Asporin (rASPN) treatment during hypoxia and reoxygenation in human cardiomyocytes enhanced autophagy and suppressed apoptosis, suggesting a cardioprotective role against ischemia-reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: